Epigenomics management change
12.10.2012 - Berlin-based diagnostics specialist Epigenomics AG has named its current Chief Financial Officer Dr. Thomas Taapken as the new Chief Executive Officer, effective 1 October 2012.
He will replace Geert Nygaard who will leave the Executive Management of the company. “On behalf of the Board of Directors, I would like to thank Geert Nygaard for his dedication to the Company for the past five and half years", said Heino von Prondzynski, Epigenomics’ Chairman of the Board. Prodzynski, a former Head of Roche Diagnostics, joined the company's board in March this year. He is regarded as a renowned industry expert. Epigenomics has faced several changes in the company's business strategy in the recent years. Taapken joined Epigenomics in April 2011 as Chief Financial Officer from Biotie Therapies (Finland). From 2005-2008 Taapken worked with elbion NV, which was then acquired by Biotie Therapies.